

## Invitation to SynAct's interim report Q4 2023 presentation

**SynAct Pharma AB (publ) ("SynAct") will publish its Q4 report for 2023 on February 23 at 07.30 CET.**

The company will host a conference call and online presentation on the same day at 15.00 CET. Torbjørn Bjerke, CEO, CFO Björn Westberg and Chief Business Officer Jim Knight will give an update on the development progress and financial results and will include a Q&A. The presentation will be made available on the website following the event.

The webcast will be live via the link: <https://ir.financialhearings.com/synact-pharma-q4-2023/register>

If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.

<https://conference.financialhearings.com/teleconference/?id=5003879>

### **For further information, please contact:**

#### **Torbjørn Bjerke**

CEO, SynAct Pharma AB

Phone: +46 727 44 41 58

Email: [TBJE@synactpharma.com](mailto:TBJE@synactpharma.com)

Email: [investor.relations@synactpharma.com](mailto:investor.relations@synactpharma.com)

#### **About SynAct Pharma AB**

SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For more information: [www.synactpharma.com](http://www.synactpharma.com).

#### **Attachments**

[Invitation to SynAct's interim report Q4 2023 presentation](#)